Last reviewed · How we verify

Elion Therapeutics, Inc. — Portfolio Competitive Intelligence Brief

Elion Therapeutics, Inc. pipeline: 0 marketed, 0 filed, 0 Phase 3, 2 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 0 Phase 3 2 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

No leading-phase drugs tracked for this sponsor.

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Dong-A ST Co., Ltd. · 1 shared drug class
  2. Graceway Pharmaceuticals, LLC · 1 shared drug class
  3. Hadassah Medical Organization · 1 shared drug class
  4. Hatem AbuHashim · 1 shared drug class
  5. Janssen Pharmaceutical K.K. · 1 shared drug class
  6. Jiangsu Aosaikang Pharmaceutical Co., Ltd. · 1 shared drug class
  7. MEDA Pharma GmbH & Co. KG · 1 shared drug class
  8. Apotex Inc. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Elion Therapeutics, Inc.:

Cite this brief

Drug Landscape (2026). Elion Therapeutics, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/elion-therapeutics-inc. Accessed 2026-05-16.

Related